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       Schistosomiasis, also known as Bilharzia, is a waterborne parasitic disease that 
affects over 230 million people worldwide accounting for 1.44 million disability-
adjusted life years lost.(1, 2) It is caused by trematode parasites of the genus 
Schistosoma, which have intricate life cycles requiring human freshwater contact and 
the presence of a suitable snail vector. Transmission occurs during freshwater contact, 
as cercariae penetrate human skin and migrate via major blood vessels to final venous 
plexuses. The lifespan of a schistosome ranges between 3-10 years but can live up to 
40 years.  (1) 
       Table 1 summarizes the major species are relevant to human populations. The most 
prevalent are Schistosoma (S.) haematobium and S. mansoni, in sub-Saharan Africa and 
S. japonicum in Asia.(1) 
       Schistosomiasis, the disease caused by Schistosoma infection, is comprised of two 
clinical syndromes; intestinal schistosomiasis or urogenital schistosomiasis, depending 
on the parasite’s vascular home (Table 1). Morbidity relates to a hyper-immune 
response to egg antigen release, causing a granulomatous reaction impairing organ 
functioning.(1, 3) 
     This review aims to summarize the most common clinical manifestations of 
schistosomiasis in different populations of children (migrants vs. returned travelers 
after short stays) with a proposed screening and treatment algorithm (Figure 1). 
 
Epidemiology 
      Schistosomiasis, is as ancient as humankind and still dangerously modern, with 78 
countries currently endemic. (1) In endemic settings, a child’s initial infection can occur 
as early as their first bath if the water, commonly fetched by mothers from rivers or 




lake shores, is infested with cercariae.(1, 3) Classically, the highest prevalence and 
intensity of active infections occur in young adolescents and decrease in adulthood.(1) 
High intensity infections usually correlate with more overt morbidity outcomes, but 
more sensitive diagnostic tools are now revealing important morbidities associated 
with lower worm burdens, particularly relevant for children.(3, 4) Isolating 
schistosomiasis as the attributable diagnosis becomes a challenge, as these morbidities 
are often confounded by other endemic conditions including malaria, soil-transmitted 
helminths, food scarcity, and social neglect. (1) 
 
Could this child have schistosomiasis?  
          The clinician should start by obtaining a thorough clinical history with special 
attention to travel history and an emphasis on exposure; where and how. Has the child 
travelled in, lived in, or migrated from an area that is endemic for schistosomiasis? The 
clinician should access information on country-specific parasite prevalence  
(https://www.who.int/gho/neglected_diseases/schistosomiasis/en/) (Table 1).(1) 
Importantly, has the child been in contact with freshwater bodies (swimming, boating, 
wading, washing) in rivers, lakes, waterfalls or ponds? A common misconception is that 
transmission does not occur in rapidly flowing water—disproven by recent epidemics 
among white water rafting and kayaking expeditions. The length of exposure and 
frequency of reinfections also matters. Intensity of infection will be greater with more 
prolonged water contact, including recurrent exposures, but there is no minimum 
exposure time for transmission to occur; a few minutes is all that is needed for cercariae 
(emerging from the snail host), to penetrate human skin.(1) 
      The second important factor to consider is clinical presentation. Children’s signs and 
symptoms can be remarkably different from those found in adults and adolescents, and 




these signs and symptoms vary by species. Further, clinical features will often differ 
between children born and raised in endemic countries compared to those experienced 
by returning travelers. Lastly, in either setting, clinicians should still have a high index 
of suspicion even if the clinical picture is not congruent with a ‘classic’ diagnosis of 
schistosomiasis. In particular, ectopic site presentations are commonly found in 
returned travelers or those with only brief exposure histories. 
 
Acute (Early) schistosomiasis 
     For this review, we define early schistosomiasis as any clinical presentation within 
the first two to three months after exposure. This definition is based on timing of adult 
worm maturation and initial egg-shedding, which occurs approximately 4-6 weeks 
after infection, triggering an initial hyper-immune host response. A full antibody 
response can take up to two to three months from initial cercarial penetration, making 
a serological diagnosis of acute schistosomiasis challenging.(5) Early schistosomiasis 
has important diagnostic and treatment limitations and relies on clinical diagnosis and 
supportive treatment.  
     Two non-species-specific clinical presentations comprise early schistosomiasis; 
cercarial dermatitis and acute schistosomiasis, also known as Katayama Syndrome. (6) 
Among residents in endemic settings, cercarial dermatitis, also known as ‘swimmers 
itch’, is not a common early presentation and could be easily overlooked. In returned 
travelers, a history of self-limited urticarial rash minutes to hours after freshwater 
exposure is highly suggestive of cercarial dermatitis.  
      Katayama Syndrome, or acute schistosomiasis, is a serum-sickness-like syndrome 
with acute onset of fever, abdominal pain, rash and eosinophilia 4-6 weeks after 
freshwater exposure. It is primarily seen in returned travelers or immigrants to 




endemic areas whose initial exposure to schistosome antigens occurs at an age older 
than first exposure among local residents.(6) A differential diagnosis should rule out 
alternative entities, particularly malaria, which is often co-endemic with 
schistosomiasis.(5) 
 
Chronic (Late) schistosomiasis 
       The most common manifestation of schistosomiasis, both in returned travelers and 
residents from endemic areas, is fatigue, likely occurring one to two months from initial 
infection. This symptom is non-specific and challenging to dissociate from other causes 
of asthenia.(3, 7)  
      After initial childhood infection, reinfection occurs frequently for children living in 
endemic settings, leading to chronic manifestations with increasing levels of organ 
fibrosis. (7)The tissue findings of chronic schistosomiasis range from a ‘soft’ polyp that 
reverses easily with anti-parasitic therapy, to a calcified granuloma that is more 
intractable to treatment.(1) The chronic manifestations detailed in this section are 
more likely to be found in children who are residents or migrants from an endemic area 
than in short-stay returned travelers. However, an untreated returned traveler can also 
present with some of the signs and symptoms detailed below.  
 
Insult to children’s growth and development 
Prolonged pro-inflammatory states are deleterious for a child’s normal growth and 
development. The cumulative effect of schistosome infections at younger ages has been 
shown to cause growth stunting via inhibition of the growth hormone-insulin growth 
factor axis, responsible for linear bone growth. This effect is mediated by pro-
inflammatory cytokines.(3) Schistosomiasis-associated anemia has a multifactorial 




etiology; ‘iron trapping’ via the release of the hepatic hormone, hepcidin and iron 
deficiency anemia, as a direct manifestation of iron loss from active bleeding. 
Downstream clinical manifestations of depleted tissue oxygenation include decreased 
aerobic capacity(1) and cognitive deficits.(7, 8)  
 
Intestinal and hepatosplenic schistosomiasis 
       Parasites living in the mesenteric veins (S. mansoni, S. japonicum) excrete eggs into 
the intestinal lumen and the eggs induce perforations as they exit, causing local 
inflammation and bleeding that can be detected as blood in the stool. (1) About half of 
the eggs excreted fail to exit and remain entrapped in the intestinal mucosa, evolving 
into eosinophilic granulomas.  
      Adult worm pairs circulate between the mesenteric plexus and the portal vein, 
allowing their eggs to flow along the portal system into the liver. There, trapped eggs 
induce local scarring, yielding peri-portal fibrosis, also known as Symmers fibrosis, 
which disseminates radially into the periphery of the liver. The gallbladder is 
frequently involved and can sometimes precede liver fibrosis. Young children were not 
thought to be affected by liver fibrosis until late adolescence, but recent population 
surveys have disproven this fact.(3) 
       The hepatic parenchyma remains normal in uncomplicated cases, preserving liver 
function until the late fibrotic stages. Late complications include portal hypertension 
leading to congestive splenomegaly, esophageal varices and upper gastrointestinal 
bleeding. These complications are infrequently seen in children. However if present, 
other comorbidities should be considered and in particular portal vein thrombosis, and 
hepatitis due to HBV, HCV and others. Because the progression of disease is a function 
of both the duration and cumulative intensity of infection, children who have lived for 




one year or longer in an endemic area (especially with prolonged freshwater exposure) 




     Adult S. haematobium worm pairs reside in the vesicular plexus draining blood from 
the genitourinary system. Eggs entrapped in the pelvic organs, cause both acute and 
chronic inflammation. In children, the defining symptom for urogenital schistosomiasis 
is hematuria, which often presents with suprapubic pain, dysuria, urinary frequency, 
or burning during micturition.(1) Advanced urinary manifestations can present with 
obstructive uropathy (hydroureter and/or hydronephrosis), which can lead to 
ascending bacterial superinfection and renal dysfunction. There is a well-established 
link between prolonged exposure to S. haematobium and squamous cell carcinoma of 
the bladder, presenting at a younger age than common bladder neoplasms but not 
usually seen in children.(1) 
         Until recently, genital schistosomiasis has been a neglected morbidity, partly due 
to cultural challenges and difficulties in diagnosis. External genital granulomas can be 
found in both boys and girls and symptoms can present before sexual debut. Symptoms 
are indistinguishable from those of sexually transmitted infection (STI), highlighting 
the need for a high index of suspicion for genital schistosomiasis in the management of 
suspected STI. Female genital schistosomiasis has been linked to increased prevalence 
of HIV and possibly to increased risk of cervical cancer.(9) 
 
Ectopic sites 




      Through the circulation, both eggs and worm pairs can lodge in ectopic sites. 
Common locations include the lungs and the central nervous system, but schistosomes 
have been found in the pericardium, the appendix, and in cutaneous tissues. 
Myelopathy, presenting as transverse myelitis, is most commonly seen in S. japonicum 
and S. mansoni, and less frequently in S. haematobium infections. Cerebral 
schistosomiasis can present with seizures and symptoms of a space-occupying lesion 
caused by local granulomatous inflammation. (1) 
 
Diagnosis of Schistosome Infection 
        In acute (early) schistosomiasis, the diagnosis is clinical and is based on exposure 
history, signs, and symptoms, because early laboratory testing is often unrevealing. (6) 
 In chronic schistosomiasis, Schistosoma eggs are detected by microscopy in urine or 
stool, depending on the species. Parasitology egg-counting methods are helpful, albeit 
insensitive, in quantifying the intensity of infection.(1) S. mansoni and S. japonicum can 
be diagnosed by urine circulating cathodic antigen (CCA) detection. (5)  
        For all Schistosoma species infections, the circulating anodic antigen (CAA) from 
blood or urine can detect as little as one worm pair, but is not yet commercially 
available. CAA is particularly useful in returned travelers classically harboring light 
infections.(5)  
      Serology for anti-schistosome antibody is helpful in returned travelers, as a definite 
measure of exposure. However, it remains positive after treatment and is therefore not 
useful to measure treatment efficacy.(5) 
 
 




Diagnosis of Disease 
      Schistosoma infection-related morbidity should be suspected if the history suggests 
a possible freshwater exposure. Functional morbidities due to schistosomiasis in 
children are easily overlooked and are often confounded by the presence of other 
ailments.(3, 7) For different schistosome species, the morbidity assessment should 
particularly focus on manifestations in organs drained by the parasite’s preferred 
venous plexus.  
       In urogenital schistosomiasis caused by S. haematobium, a urinary tract ultrasound 
can reveal bladder polyps or bladder wall irregularities and findings related to ureteral 
outlet obstruction and subsequent hydronephrosis. Bladder calcifications may be 
noted, but are better seen on standard x-ray. (1) Genital tract changes cannot be 
diagnosed by ultrasound. Colposcopy can reveal pathognomonic lesions. Boys may 
have hematospermia or a change of sperm consistency. While symptoms are 
indistinguishable from STI, if caused by schistosomiasis, they may improve with 
praziquantel therapy. (9) 
      For intestinal schistosomiasis, non-specific proxy markers of inflammation, fecal 
occult blood and calprotectin, can be utilized to monitor disease severity.(1) Advanced 
stages of hepatosplenic disease can be diagnosed by liver ultrasound. 
 
Management 
      For cercarial dermatitis, anti-pruritic agents may help symptoms. Steroids may play 
a role in reducing inflammation in Katayama syndrome.(6) Praziquantel, the only 
available drug to treat schistosomiasis, targets only adult worms and is therefore not 
effective in early disease. A second dose can be given after juvenile worms fully mature. 




(Table 1) WHO recommends praziquantel at a dose of 40-60 mg/kg, but the best drug 
regimen for individual schistosome species is still not known.(3) Tablet crushing 
remains the only viable option for under-fives, provided there is a safe monitoring 
environment, until a pediatric formulation becomes available.(10) 
 
Conclusions 
      In summary, clinicians should have a high index of suspicion in returned travelers 
or migrants presenting from a schistosomiasis endemic area with reported freshwater 
exposure. Functional morbidities are important to recognize in children, albeit possibly 
confounded by other infections or co-morbidities. However, this should not preclude 





































































































Early :     urticarial rash 
                  abdominal pain, fever 
                  blood in stools, anemia      
 
 
Late:        growth retardation, 
                  blood in stools, anemia      
                  decreased fitness, 
                  impaired cognition, 
                  fatigue 
                  portal hypertension 
                  transverse myelitis 
                  seizures 
 
Infection: 
Eggs in stool by microscopy 
CCA in urine 















Late: Praziquantel  
 
40 mg/kg/day PO  
for 1 or 2 days  
 














Early:      urticarial rash     
                  abdominal pain, fever 
                  dysuria, hematuria, 
genitourinary symptoms 
 
Late:       growth retardation, anemia, 
decreased fitness, impaired 
cognition, renal failure, 
hydroureter/hydronephrosis, 
dyspareunia, infertility,  
                  genital pain, discharge, 
granulomas, polyps 
                  bladder carcinoma 




Eggs in urine by microscopy 
CAA in plasma or urine 
Urine PCR 














Late: Praziquantel  
 
40 mg/kg/day PO  
for 1 or 2 days  
 












Southeast Asia  
The Philippines 
 
Early:      urticarial rash 
                  abdominal pain, fever 
                  blood in stools, anemia      
 
Late:        growth retardation, 
                  blood in stools, anemia      
                  decreased fitness, 
                  impaired cognition, 
                  fatigue 
 
Infection: 
Eggs in stool by microscopy 
CCA in urine 









Late: Praziquantel  
 
60 mg/kg/day divided tid PO  
for 1 or 2 days  
 
Repeat after 4-6 weeks 






























                  portal hypertension 
                  transverse myelitis 













                 Trichula snail 
Southeast Asia 
Early:      urticarial rash 
                  abdominal pain, fever 
                  blood in stools, anemia      
 
Late:        growth retardation, 
                  blood in stools, anemia      
                  decreased fitness, 
                  impaired cognition, 
                  fatigue 
                  portal hypertension 
                  transverse myelitis 




Eggs in stool by microscopy 
CCA in urine 

















60 mg/kg/day  
divided in three doses PO  
for 1 or 2 days  
 









freshwater    




Early:      urticarial rash 
                  abdominal pain, fever 
                  blood in stools, anemia      
 
Late:        growth retardation, 
                  blood in stools, anemia      
                  decreased fitness, 
                  impaired cognition, 
                  fatigue 
                  portal hypertension 
                  transverse myelitis 
                  seizures 
 
Infection: 
Eggs in stool by microscopy 
CCA in urine 

















40 mg/kg/day PO  
for 1 or 2 days  
 
Repeat after 4-6 weeks 
*Early: 0-2 months after exposure 
*Late: > 2 months after exposure 
Table 1: Human relevant Schistosoma spp. with their geographical distribution, clinical presentation, and suggested treatment.   
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